Skip to main content

Table 1 Patient’s characteristics and clinical data comparing the two study groups

From: Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial

Characteristics

1 g/8 h group (N = 16)

2 g/8 h group (N = 15)

P value

Demographic and clinical data

 Male, n (%)

12 (75)

13 (86.7)

0.654

 Age (years)

64.0 (20.0)

75.0 (14.0)

0.202

 Body weight (kg)

74.0 (14.8)

70.0 (15.0)

0.495

 BMI (kg/m2)

26.8 (3.8)

25.5 (6.4)

0.338

 Charlson Comorbidity Index

4.0 (3.5)

6.0 (4.0)

0.033

 APACHE II scorea

13.0 (10.8)

15.0 (6.0)

0.423

Other clinical datab

 Type of pneumonia, n (%)

  

> 0.999

  Ventilator-associated pneumonia

4 (25)

4 (26.7)

 

  Hospital-acquired pneumonia

12 (75)

11 (73.3)

 

 SOFA score

5 (4)

5 (5)

0.830

 Septic shock, n (%)

4 (25)

3 (20)

> 0.999

 Sepsis, n (%)

10 (62.5)

12 (80)

0.433

 Concomitant bacteremia, n (%)

3 (18.8)

2 (13.3)

> 0.999

 Fluid overload, n (%)

2 (12.5)

6 (40)

0.113

 Mechanical ventilation, n (%)

4 (25)

4 (26.7)

> 0.999

 GFR (mL/min/1.73 m2)

103.0 (33.0)

85.0 (30.0)

0.281

  GFR < 90 mL/min/1.73 m2, n (%)

6 (37.5)

9 (60.0)

0.210

  GFR > 120 mL/min/1.73 m2, n (%)

2 (12.5)

3 (13.3)

> 0.999

 C-reactive protein (mg/dL)

15.0 (26.9)

17.5 (14.1)

0.654

 Procalcitonin (ng/mL)

0.8 (2.1)

0.9 (3.6)

0.375

 Total serum protein (g/dL)

5.2 (1.4)

5.1 (1.0)

0.830

 Serum albumin (g/dL)

2.9 (0.9)

2.8 (0.6)

0.599

Clinical and microbiological outcomes

 Clinical cure, n (%)

13 (81.3)

11 (73.3)

0.685

 Length of ICU stay (days)

19.9 (15.8)

18.2 (17.4)

0.730

 Length of hospital stay (days)

39.5 (54.8)

28.0 (55.0)

0.682

 Microbiological eradication, n (%)

4 (25.0%)

7 (46.7%)

0.494

 Seven-day all-cause mortality, n (%)

0 (0)

0 (0)

> 0.999

 Thirty-day all-cause mortality, n (%)

1 (6.3)

1 (6.7)

> 0.999

 In-hospital mortality, n (%)

1 (6.3)

1 (6.7)

> 0.999

Microbiological data: specie, n (%)/MIC (mg/L)c

 Gram-negative bacteria

6 (37.5)

7 (46.7)

0.605

 MDR Gram-negative bacteria

3 (18.8)

2 (13.3)

> 0.999

 Pseudomonas aeruginosa (PA)

3 (18.8)

2 (13.3)

> 0.999

  Multi-susceptible PA

2 (12.5)/≤ 2

0 (0)

0.484

  MDR PA

0 (0)

1 (6.7)/16

0.484

  XDR PA

1 (6.3)/8

1 (6.7)/32

> 0.999

 Enterobacteriaceae

3 (18.8)

3 (20.0)

> 0.999

  ESBL producers

3 (18.8) / ≤2

0 (0)

0.226

 Other Gram-negative bacteria

1 (6.3)/≤ 2

3 (20.0)/≤2

0.333

  1. MDR multidrug-resistant, XDR extensively drug-resistant, ESBL extended-spectrum beta-lactamases
  2. aCalculated at the beginning of ICU admission
  3. bData at the onset of treatment
  4. cBased on EUCAST breakpoints